Zimbabwe has turned down a major American healthcare agreement valued at $367m (272 million pounds) spanning five years because of the United States' demand for confidential biological samples.
The decision became public after a internal memorandum dated December was disclosed, which showed President Emmerson Mnangagwa felt the deal was "lopsided".
An official spokesperson later clarified that the United States was seeking health data for research and commercial gain but was not willing to share the resulting advantages from any future vaccines.
"We are forced to start the difficult and regrettable task of ending our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had donated over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for more dialogue to secure a deal agreeable to all parties so the country's vital HIV treatment initiative can proceed.
Wider Implications
Zimbabwe's decision follows a comparable situation in neighbouring Kenya, where a high court blocked a related health funding agreement after legal challenges were raised about the safety of Kenyans' medical information.
After resuming office last year, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
The agency had administered aid for the American government, but Trump argued its spending was "inefficient" and his administration was pursuing direct bilateral agreements to enhance transparency and responsibility.
As per reports, 16 nations in Africa have to date signed these new health pacts, representing over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
The money for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership could have provided significant advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently on HIV treatment through US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Our nation was requested to provide its genetic material and health information indefinitely, with no equivalent guarantee of benefiting from any medical innovations – like new medicines or tests – that could be developed from that provided information," he stated.
"In essence, our country would supply the raw materials for medical research without any certainty that the final treatments would be available to our people if a new pandemic emerge."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were upending structures already set up through the international organization.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to manage potential pandemics.
"This framework is intended to guarantee that when a country contributes its samples, the benefits – including medicines and cures – are shared equitably, not commercialised solely by those with the capability to create them."
The government's concerns regarding the US deal "are not meant as hostility towards the US," he added.
"We encourage continued discussions with our US partners on how future co-operation might be arranged in a way that honours the independence and interests of both nations."
Health Experts Response
A leading public health body said it recognised the government's concerns, but urged that negotiations should continue given that much of the country's Aids initiatives relied on international support.
"In cases where technical issues exist, such as those involving data governance or agreement terms, these can frequently be resolved via technical clarification and negotiated safeguards," the group said.
The situation emphasises the ongoing challenges between receiving crucial foreign assistance and protecting national sovereignty in an ever more interconnected world.